<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04161092</url>
  </required_header>
  <id_info>
    <org_study_id>SOULMATE</org_study_id>
    <nct_id>NCT04161092</nct_id>
  </id_info>
  <brief_title>The Swedish Study of Liver Transplantation for Non-resectable Colorectal Cancer Metastases</brief_title>
  <acronym>SOULMATE</acronym>
  <official_title>A Randomized Controlled, Open-label, Multicentre Study Evaluating if Liver Transplantation With Liver Grafts From Extended Criteria Donors Not Utilised for Approved Indications Increases Overall Survival in Patients With Non-resectable Isolated Liver Metastases From Colorectal Metastases, in Comparison With Best Alternative Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vastra Gotaland Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vastra Gotaland Region</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate if the addition of liver transplantation primarily utilizing liver grafts from
      extended criteria donors not utilized for approved indications to conventional treatment of
      non-resectable/ non-abatable colorectal liver metastases (CLM) increases overall survival
      compared to best alternative care.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2020</start_date>
  <completion_date type="Anticipated">June 2030</completion_date>
  <primary_completion_date type="Anticipated">December 2029</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Five-year overall survival</measure>
    <time_frame>randomization to follow up at 5 years</time_frame>
    <description>Percentage of subject who reach the endpoint of overall survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Two-year overall survival</measure>
    <time_frame>randomization to follow up at 2 years</time_frame>
    <description>Percentage of subject who reach the endpoint of overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median overall survival</measure>
    <time_frame>: Date of randomization until the date of death from any cause, assessed up to 5 years</time_frame>
    <description>Defined as time to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Date of randomization until the date of documented progression of existing lesions or appearance of new lesions, assessed up to 5 years</time_frame>
    <description>Defined as time from randomization to progress of existing lesions, or appearance of new lesions, within the liver according to RECIST criteria (version 1.1) using CT or MRI and analysed using Kaplan-Meier and the log-rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic progression-free survival</measure>
    <time_frame>Date of randomization until the date of documented progression of existing lesions or appearance of new lesions in the liver, assessed up to 5 years</time_frame>
    <description>Defined as time from randomization to progress of existing lesions in the liver , or appearance of new lesions in the liver, according to RECIST criteria (version 1.1) using CT or MRI and analysed using Kaplan-Meier and the log-rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extrahepatic recurrence-free survival</measure>
    <time_frame>Date of randomization until the date of documented appearance of new extra-hepatic lesions, assessed up to 5 years</time_frame>
    <description>Defined as time from randomization to appearance of new extra-hepatic lesions, using CT or MRI and analysed using Kaplan-Meier and the log-rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of Life assessed with Euroqol Group Questionaire 5D-3L (EQ-5D-3L)</measure>
    <time_frame>baseline, 3, 6, 12, 18, 24, 36 and 60 months</time_frame>
    <description>Assessed with EQ-5D-3L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economic evaluation</measure>
    <time_frame>baseline, 3, 6, 12, 18, 24, 36 and 60 months</time_frame>
    <description>Estimation of Quality Adjusted Life Year (QALY) assessed with EQ-5D-3L</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Liver Metastases</condition>
  <condition>Colorectal Liver Metastases</condition>
  <arm_group>
    <arm_group_label>Liver transplantation + best alternative care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients subjected to Ltx will during the waiting time receive individualized chemotherapy, with the aim to avoid side effect that make them not transplantable.
If possible, patients randomized to Ltx should be treated within 12 weeks after randomization.
If the patients progress systemically they will be treated with best alternative care.
If they progress only within the liver they continue to be transplantable until they are deemed technically not transplantable by the transplant surgeon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best alternative care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The treating physician will together with the patient decide the treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver transplantation Ltx</intervention_name>
    <description>Patients will be treated with Ltx at Sahlgrenska University Hospital, Göteborg, or Karolinska University Hospital, Huddinge.</description>
    <arm_group_label>Liver transplantation + best alternative care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best alternative care</intervention_name>
    <description>All available treatments as well as other experimental treatments are tolerated, however no cross-over to other arm will be allowed.</description>
    <arm_group_label>Best alternative care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with non-resectable, non-ablatable liver metastases from colorectal
             adenocarcinoma.

          -  Male or female 18 years or above.

          -  Primary tumour removed with an R0 resection, and histologically verified
             adenocarcinoma from colon or rectum

          -  Liver metastases measurable by MRI or CT according to RECIST version 1.1 Imaging
             within 4 weeks prior to inclusion.

          -  No signs of extrahepatic metastatic disease or local recurrence according to MRI and
             CT of thorax/abdomen and whole body Positron-emission tomography (PET)/ computed
             tomography (CT) scan.

          -  A colonoscopy performed within the last 12 months in order to exclude multifocal
             colorectal cancer (CRC) tumours.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Satisfactory blood tests: Hb ≥ 90 g/L (transfusions are permitted to achieve baseline
             hemoglobin level), White blood cell Count (WBC) &gt;3,0x109/L, Absolute neutrophil count
             (ANC) ≥ 1.5 × 10^9/L, platelet Count (PLT) &gt;75, Bilirubin&lt;2 x upper normal level,
             Aspartate aminotransferase (ASAT), Alanine aminotransferase (ALAT)&lt;5 x upper normal
             level, Calculated Creatinine clearance ≥ 50 mL/min(MDRD).

          -  Received at least 2 months of chemotherapy with no signs of progressive disease
             according to RECIST-criteria at the last evaluation before randomization.

          -  One year or more from the initial CRC diagnosis to the date of inclusion in the study

          -  Patient accepted for transplantation by a national study board

          -  Signed and dated written informed consent before the start of specific protocol
             procedures.

        Exclusion Criteria:

          -  Evidence of extrahepatic disease by PET-CT or CT-thorax/abdomen.

          -  Pregnant or breast-feeding patients. Women of childbearing potential must have a
             negative pregnancy test performed within seven days prior to the start of study.

          -  Weight loss &gt;10% the last 6 months

          -  Other malignancies within the last 5 years, except CRC and low risk tumours such as
             basaliomas.

             * Liver metastases larger than 10 cm.

          -  Pathological lymphatic nodes in the abdomen. If a patient has pathological lymphatic
             nodules in the hepatoduodenal ligament, a staging operation with histo-pathological
             examination from the nodules with no signs of tumour cell involvement has to be
             performed before inclusion.

          -  BRAF (a gene that encodes a protein called b-raf) mutation in primary tumour

          -  microsatellite instability (MSI-H) in primary tumour

          -  Previous organ transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per G Lindner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Transplant Institute, Sahlgrenska University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carl Jorns, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Transplantation Unit, Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Per G Lindnér, MD, PhD</last_name>
    <phone>+46705548400</phone>
    <email>per.lindner@vgregion.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Helena Taflin</last_name>
    <phone>+46700824799</phone>
    <email>helena.taflin@vgregion.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Transplant Institute, Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Veronica Reivell</last_name>
      <phone>+46705129087</phone>
      <email>veronica.reivell@vgregion.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Transplantation Unit, Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Carl Jorns, MC, PhD</last_name>
      <phone>+46762721845</phone>
      <email>carl.jorns@sll.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004 Jun;239(6):818-25; discussion 825-7.</citation>
    <PMID>15166961</PMID>
  </reference>
  <reference>
    <citation>Hagness M, Foss A, Line PD, Scholz T, Jørgensen PF, Fosby B, Boberg KM, Mathisen O, Gladhaug IP, Egge TS, Solberg S, Hausken J, Dueland S. Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg. 2013 May;257(5):800-6. doi: 10.1097/SLA.0b013e3182823957.</citation>
    <PMID>23360920</PMID>
  </reference>
  <reference>
    <citation>Dueland S, Guren TK, Hagness M, Glimelius B, Line PD, Pfeiffer P, Foss A, Tveit KM. Chemotherapy or liver transplantation for nonresectable liver metastases from colorectal cancer? Ann Surg. 2015 May;261(5):956-60. doi: 10.1097/SLA.0000000000000786.</citation>
    <PMID>24950280</PMID>
  </reference>
  <reference>
    <citation>Gorgen A, Muaddi H, Zhang W, McGilvray I, Gallinger S, Sapisochin G. The New Era of Transplant Oncology: Liver Transplantation for Nonresectable Colorectal Cancer Liver Metastases. Can J Gastroenterol Hepatol. 2018 Jan 10;2018:9531925. doi: 10.1155/2018/9531925. eCollection 2018. Review.</citation>
    <PMID>29623268</PMID>
  </reference>
  <reference>
    <citation>Fosby B, Melum E, Bjøro K, Bennet W, Rasmussen A, Andersen IM, Castedal M, Olausson M, Wibeck C, Gotlieb M, Gjertsen H, Toivonen L, Foss S, Makisalo H, Nordin A, Sanengen T, Bergquist A, Larsson ME, Soderdahl G, Nowak G, Boberg KM, Isoniemi H, Keiding S, Foss A, Line PD, Friman S, Schrumpf E, Ericzon BG, Höckerstedt K, Karlsen TH. Liver transplantation in the Nordic countries - An intention to treat and post-transplant analysis from The Nordic Liver Transplant Registry 1982-2013. Scand J Gastroenterol. 2015 Jun;50(6):797-808. doi: 10.3109/00365521.2015.1036359.</citation>
    <PMID>25959101</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 31, 2019</study_first_submitted>
  <study_first_submitted_qc>November 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2019</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>liver metastases</keyword>
  <keyword>liver transplant</keyword>
  <keyword>non-resectable colorectal cancer metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

